Activating kinase mutations in melanoma
AEBP1 upregulation confers acquired resistance to BRAF (V600E) inhibition in melanoma
Cotargeting histone deacetylases and oncogenic BRAF synergistically kills human melanoma cells by necrosis independently of RIPK1 and RIPK3
Macrophage migration inhibitory factor engages PI3K/Akt signalling and is a prognostic factor in metastatic melanoma
- Trunzer, Kerstin, Pavlick, Anna C., Hersey, Peter, Long, Georgina V., Lawrence, Donald, Ott, Patrick A., Amaravadi, Ravi K., Lewis, Karl D., Puzanov, Igor, Lo, Roger S., Koehler, Astrid, Kockx, Mark, Schuchter, Lynn, Spleiss, Olivia, Schell-Steven, Annette, Gilbert, Houston N., Cockey, Louise, Bollag, Gideon, Lee, Richard J., Joe, Andrew K., Sosman, Jeffrey A., Ribas, Antoni, Gonzalez, Rene, McArthur, Grant A., Hutson, Thomas E., Moschos, Stergios J., Flaherty, Keith T., Kim, Kevin B., Weber, Jeffrey S.
Reactivation of ERK and Akt confers resistance of mutant BRAF colon cancer cells to the HSP90 inhibitor AUY922
Regulation of apoptosis induced by targeting the RAF/MEK/ERK pathway in human melanoma
Therapeutic targeting of heat shock protein 90 in human colon cancer cells
Are you sure you would like to clear your session, including search history and login status?